Cardiovascular Diseases : VHIR Annual Report 2020

Vascular Biology and Metabolism (VAM)

< Back

Overview

The VAM area was created to allow a comprehensive, cooperative and multidisciplinary approach in basic, clinical and epidemiology research. The ultimate goal is the innovation and transfer of solutions in a group of diseases that are closely interrelated and that constitute the leading cause of morbidity and mortality in the world: cardio-cerebrovascular disease, diabetes-metabolic syndrome and renal impairment. The VAM area includes preclinical and clinical research staff from our center, and collaborative work with groups of the highest international prestige. VAM area includes 8 groups: Cardiovascular Pathology, Diabetes and Metabolism, Nephrology, Ophthalmology (focused on retinal vascular disease), CIBBIM-Nanomedicine and Kidney Physiopathology, Medical Molecular Imaging, Neurovascular Diseases, and Research on Aging, Frailty and Transitions in Barcelona. All groups use an integrative tridimensional approach to generate knowledge on the mechanisms of diseases to generate new diagnostic and therapeutic tools.

Publications

281
total
1353
impact factor
4.81
average impact factor

Group Leader: Ignacio Ferreira González

In 2020 we have joined a large multidisciplinary international project on aortic disease (CAMR-AI) using cardiac magnetic resonance imaging, funded by the European Commission (EU EIT Health Grant). Its aim is to advance non-invasive imaging for the personalized management of aortic diseases through an innovative software, so as to decrease mortality, morbidity, and healthcare costs. Another remarkable achievement has been the approval by the European Commission for us to join the European Reference Network in thematic areas 2 and 4 (familial cardiomyopathies and congenital heart disease). Three other projects have been funded by ISC-III and 5 by the Spanish Society of Cardiology.  Articles have been published on ischemic heart disease, aorta, arrhythmias and cardiac imaging (4D-Flow in cardiac NMR studies).  A new treatment against ischemia-reperfusion injury and adverse myocardial remodeling based on the inhibition of calpains has led to knowledge transfer to industry and society.

 

VHIR Annual Report 2020